Dennis Mulroy
Fortune : 692 332 $ au 30/09/2026
Fortune : 692 332 $ au 30/09/2026
Mr. Dennis M.
Mulroy, CPA, is a Chief Financial Officer at Arcturus Therapeutics Holdings, Inc. Mr. Mulroy was previously employed as a Chief Financial Officer by AnaptysBio, Inc., a CEO, Chief Financial & Accounting Officer by La Jolla Pharmaceutical Co., a Chief Financial Officer, Treasurer & Director by Tissue Repair Co., a Chief Financial Officer by Post-Hypothermia Corp., a Chief Financial Officer by Aries Ventures, Inc., a Chief Financial Officer by Gene Biotherapeutics, Inc., a Chief Financial Officer by Molecular Imaging Corp., a Chief Financial Officer by SeraCare Life Sciences, Inc., and a Chief Financial Officer by Bioceutix, Inc. He received his undergraduate degree from the University of San Diego.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ANAPTYSBIO, INC. 0,05 % | 01/06/2026 | 13 775 ( 0,05 % ) | 692 332 $ | 30/09/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ARCTURUS THERAPEUTICS HOLDINGS INC. | Directeur Financier/CFO | 01/05/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
| ANAPTYSBIO, INC. | Directeur Financier/CFO | 20/04/2026 |
| LA JOLLA PHARMACEUTICAL COMPANY | Directeur Général | 31/05/2020 |
Taxus Cardium Pharmaceuticals Group, Inc.
Taxus Cardium Pharmaceuticals Group, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes angiogenic gene therapy products for cardiovascular disease | Directeur Financier/CFO | 03/04/2015 |
Tissue Repair Co.
Tissue Repair Co. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops wound healing products for chronic wounds and aftercare | Directeur Financier/CFO | 02/01/2013 |
Aries Ventures, Inc.
Aries Ventures, Inc. Financial ConglomeratesFinance Financial investment vehicle | Directeur Financier/CFO | 23/01/2006 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 11 |
|---|---|
La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and commercializes patients life-threatening conditions | Health Technology |
Aries Ventures, Inc.
Aries Ventures, Inc. Financial ConglomeratesFinance Financial investment vehicle | Finance |
Molecular Imaging Corp.
Molecular Imaging Corp. Medical/Nursing ServicesHealth Services Provides molecular imaging services | Health Services |
SeraCare Life Sciences, Inc.
SeraCare Life Sciences, Inc. Medical SpecialtiesHealth Technology Develops and manufactures biological based products to serve the global life sciences industry | Health Technology |
Tissue Repair Co.
Tissue Repair Co. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops wound healing products for chronic wounds and aftercare | Health Technology |
AnaptysBio, Inc.
AnaptysBio, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company | Health Technology |
University of San Diego
University of San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Post-Hypothermia Corp.
Post-Hypothermia Corp. Medical SpecialtiesHealth Technology Manufactures and markets temperature modulation therapy devices | Health Technology |
Taxus Cardium Pharmaceuticals Group, Inc.
Taxus Cardium Pharmaceuticals Group, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes angiogenic gene therapy products for cardiovascular disease | Health Technology |
Bioceutix, Inc. | |
Arcturus Therapeutics Holdings, Inc.
Arcturus Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national